JP2023551734A5 - - Google Patents

Info

Publication number
JP2023551734A5
JP2023551734A5 JP2023533830A JP2023533830A JP2023551734A5 JP 2023551734 A5 JP2023551734 A5 JP 2023551734A5 JP 2023533830 A JP2023533830 A JP 2023533830A JP 2023533830 A JP2023533830 A JP 2023533830A JP 2023551734 A5 JP2023551734 A5 JP 2023551734A5
Authority
JP
Japan
Application number
JP2023533830A
Other languages
Japanese (ja)
Other versions
JPWO2022120137A5 (https=
JP2023551734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061755 external-priority patent/WO2022120137A1/en
Publication of JP2023551734A publication Critical patent/JP2023551734A/ja
Publication of JPWO2022120137A5 publication Critical patent/JPWO2022120137A5/ja
Publication of JP2023551734A5 publication Critical patent/JP2023551734A5/ja
Pending legal-status Critical Current

Links

JP2023533830A 2020-12-04 2021-12-03 眼の疾患を治療するための組成物及び方法 Pending JP2023551734A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
US63/121,629 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (3)

Publication Number Publication Date
JP2023551734A JP2023551734A (ja) 2023-12-12
JPWO2022120137A5 JPWO2022120137A5 (https=) 2024-12-10
JP2023551734A5 true JP2023551734A5 (https=) 2024-12-10

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533830A Pending JP2023551734A (ja) 2020-12-04 2021-12-03 眼の疾患を治療するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240059765A1 (https=)
EP (1) EP4255485A4 (https=)
JP (1) JP2023551734A (https=)
KR (1) KR20230117192A (https=)
CN (1) CN116782940A (https=)
AU (1) AU2021391800A1 (https=)
CA (1) CA3200976A1 (https=)
CL (1) CL2023001596A1 (https=)
IL (1) IL303289A (https=)
MX (1) MX2023006591A (https=)
WO (1) WO2022120137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
KR20250006238A (ko) * 2022-04-29 2025-01-10 애넥슨, 인코포레이티드 안구 질환을 치료하기 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023551734A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102020022030A2 (https=)
CL2025003474A1 (es) Sales agonistas de sstr4.
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)